Price reduction of generic drugs after loss of exclusivity in the U.S. 2015

Monthly price reduction of generic drugs after loss of exclusivity in the United States as of 2015

by Statista Research Department, last edited Feb 1, 2016
Price reduction of generic drugs after loss of exclusivity in the U.S. 2015 This statistic represents the monthly price reduction of generic drugs after their loss of exclusivity in the United States, as of 2015. After 12 months of patent loss, oral drugs suffered a price reduction of some 66 percent.
Show more

Monthly price reduction of generic drugs after loss of exclusivity in the United States as of 2015

Loading statistic...
Months since loss of exclusivityOral medicinesAll medicines
12-66%-51%
24-74%-57%
36-77%-66%
48-78%-66%
60-80%-67%
72-80%-77%
84-80%-78%
96-81%-80%
108-81%-78%
120-81%-77%
Months since loss of exclusivityOral medicinesAll medicines
12-66%-51%
24-74%-57%
36-77%-66%
48-78%-66%
60-80%-67%
72-80%-77%
84-80%-78%
96-81%-80%
108-81%-78%
120-81%-77%
Download Settings Share
Download started
Please be patient - this may take a moment
by Statista Research Department, last edited Feb 1, 2016
This statistic represents the monthly price reduction of generic drugs after their loss of exclusivity in the United States, as of 2015. After 12 months of patent loss, oral drugs suffered a price reduction of some 66 percent.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on "Generics and biosimilars"
  • Global overview
The most important statistics
  • Top companies
  • U.S. market
  • Patent expiration
  • Savings
  • Biosimilars
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.